InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Zymeworks Inc.

ZYME Clue Score44
United States Fiscal year ends December CIK 0001937653 Results filed 6 Aug 2026
Add to watchlist

What the insiders did Net buying

Individual transactions

23
Insider
Date
Role
Action
Shares
Price
Amount
Adam Schayowitz
9 Oct 2026
EVP, Head of R&D
Sold after exercise
13,832
$25.85
$357.56K
Kenneth Galbraith
12 Jan 2026
Chair & CEO
Sold after exercise
30,424
$22.67
$689.82K
Paul Andrew Moore
12 Jan 2026
Chief Scientific Officer
Sold after exercise
9,560
$22.67
$216.76K
Jeffrey T L Smith
12 Jan 2026
EVP & Chief Medical Officer
Sold after exercise
9,310
$22.67
$211.09K
Mark Hollywood
12 Jan 2026
EVP & Chief Operating Officer
Sold after exercise
6,120
$22.67
$138.76K
Paul Andrew Moore
5 Jan 2026
Chief Scientific Officer
Sold after exercise
10,821
$25.10
$271.57K
Paul Andrew Moore
5 Jan 2026
Chief Scientific Officer
Sold after exercise
9,289
$25.10
$233.13K
Kenneth Galbraith
5 Jan 2026
Chair & CEO
Sold after exercise
31,686
$25.10
$795.22K
Kenneth Galbraith
5 Jan 2026
Chair & CEO
Sold after exercise
22,657
$25.10
$568.62K
Jeffrey T L Smith
5 Jan 2026
EVP & Chief Medical Officer
Sold after exercise
10,538
$25.10
$264.47K
Kenneth Galbraith
22 Dec 2025
Chair & CEO
Sold after exercise
47,528
$27.02
$1.28M
Jeffrey T L Smith
6 Jan 2025
EVP & Chief Medical Officer
Sold after exercise
11,110
$14.92
$165.81K
Kenneth Galbraith
6 Jan 2025
Chair & CEO
Sold after exercise
33,406
$14.92
$498.55K
Kenneth Galbraith
6 Jan 2025
Chair & CEO
Sold after exercise
23,885
$14.92
$356.46K
Paul Andrew Moore
6 Jan 2025
Chief Scientific Officer
Sold after exercise
11,408
$14.92
$170.25K
Paul Andrew Moore
6 Jan 2025
Chief Scientific Officer
Sold after exercise
9,792
$14.92
$146.14K
Paul Andrew Moore
5 Jan 2024
Chief Scientific Officer
Sold after exercise
7,460
$10.65
$79.47K
Christopher Astle
5 Jan 2024
SVP & Chief Financial Officer
Sold after exercise
4,563
$10.65
$48.61K
Kenneth Galbraith
5 Jan 2024
Chair & CEO
Sold after exercise
18,198
$10.65
$193.85K
Christopher Astle
11 Dec 2023
SVP & Chief Financial Officer
Sold after exercise
886
$9.13
$8.09K
Neil A Klompas
10 Mar 2023
President & COO
Sold after exercise
2,977
$7.83
$23.30K
Christopher Astle
12 Dec 2022
SVP & Chief Financial Officer
Sold after exercise
887
$6.01
$5.33K
Neil Josephson
10 Nov 2022
Chief Medical Officer
Sold after exercise
2,475
$8.10
$20.05K
Show all 69 transactions →

What was left out

Form 4 filings counted 94
Amendments (4/A) skipped 4
Filings about a different issuer 0
Unreadable filings 0
Joint filings 10
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 23
Sales at will 3
Transactions with no price 0
Shares from compensation/vesting 6,219,960
History held since 17 Oct 2022